Suzhou Tongxin Medical Technology Co., Ltd. has recently secured over US$100 million in strategic financing, a round led by a consortium of prominent investment firms. This influx of capital will primarily be directed towards bolstering the company's international footprint, fostering technological advancements, and enhancing its domestic commercialization infrastructure. Tongxin Medical's self-developed CH-VAD, the first domestically produced ventricular assist device to receive market approval, has heralded a new era of "artificial heart" therapy for advanced heart failure in China. Additionally, the company's next-generation product, BrioVAD, has achieved significant milestones, becoming the first active implantable medical device from China to enter clinical trials in the United States and successfully completing its first human implantation there. This accomplishment signifies the successful penetration of China's high-end medical equipment into the internationally competitive market. Currently, BrioVAD is undergoing large-scale confirmatory research and has secured coverage under the US Medicare program, indicating broad commercialization potential. Tongxin Medical is steadfastly advancing its globalization strategy, aiming to establish itself as a global pioneer in innovative solutions for advanced heart failure.